REGULATED INFORMATION
PRESS RELEASE
Transparency notifications
pursuant to Article 14 of the Law of May 2, 2007
Leuven (Belgium) - March 30, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received transparency notifications pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.
Summary of the notifications
It concerns the following two notifications:
1. Content of the notification by BNP Paribas Asset Management SA
Date of the notification: March 23, 2018.
Reason of the notification: acquisition or disposal of voting securities or voting rights/downwards crossing of the lowest threshold.
Person subject to the notification requirement: BNP Paribas Asset Management SA (with address at SA 47000 - 75318 Paris Cedex 09, France), who is a parent undertaking/controlling person.
Date on which the threshold was crossed: March 19, 2018.
Threshold that was crossed: 3%.
Denominator: 296,067,856.
Details of the notification: following the acquisition or disposal of voting securities or voting rights, the number of voting rights was as follows:
Total: 8,497,061 voting rights (2.87% of the total number of voting rights).
Chain of controlled undertakings through which the holdings are effectively held: the subsidiaries BNP Paribas Asset Management UK Limited and BNP Paribas Asset Management France SAS are controlled by the parent company BNP Paribas Asset Management SA, which in turn is controlled by BNP Paribas SA which benefits from an exemption to aggregate its participations with the participations of its subsidiaries investment companies pursuant to article 21, §2 of the Royal Decree of February 14, 2008 regarding the publication of major holdings.
Additional information: BNP Paribas Asset Management UK Limited and BNP Paribas Asset Management France SAS are investment companies who exercise voting rights in a discretionary way.
2. Content of the notification of Melqart Asset Management LP
Date of the notification: March 22, 2018.
Reason of the notification: acquisition of financial instruments that are treated as voting securities.
Person subject to the notification requirement: Melqart Asset Management LP c/o Melqart Asset Management (UK) Ltd (with address at PO Box 309, Ugland House, Grand Cayman, KY1-1104), who is a parent undertaking/controlling person.
Date on which the threshold was crossed: March 21, 2018.
Threshold that was crossed: 5%.
Denominator: 296,067,856.
Details of the notification: following the acquisition of financial instruments that are treated as voting securities, the number of voting rights was as follows:
and the number of equivalent financial instruments was as follows:
Chain of controlled undertakings through which the holding is effectively held: Melqart Asset Management LP controls Melqart Asset Management (UK) Ltd.
Additional information: Melqart Asset Management (UK) Ltd is the investment manager of Melqart Opportunities Master Fund Ltd. Melqart Asset Management (UK) Ltd is a management company that can exercise the voting rights at its own discretion without specific instructions.
This press release and the above-mentioned transparency notifications can be consulted on our website:
For more information:
TiGenix
Claudia Jiménez
Senior Director Investor Relations and Communications
Tel: +34918049264
Claudia.jimenez@tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels and NASDAQ: TIG) is an advanced biopharmaceutical company developing novel therapies for serious medical conditions by exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells.
TiGenix' lead product, Alofisel, successfully completed a European Phase III clinical trial for the treatment of complex perianal fistulas - a severe, debilitating complication of Crohn's disease. A global Phase III trial intended to support a future U.S. Biologic License Application (BLA) started in 2017. TiGenix has entered into a licensing agreement with Takeda, a global pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to develop and commercialize Alofisel for complex perianal fistulas outside the U.S. TiGenix' second adipose-derived product, Cx611, is undergoing a Phase I/II trial in severe sepsis - a major cause of mortality in the developed world. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain) and Cambridge, MA (USA). For more information, please visit http://www.tigenix.com.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.